The foundation of a BHV‑1 DIVA test is a competitive ELISA built around the glycoprotein E (gE) deletion. The required immunoassay format is a competitive (blocking) ELISA. The essential reagent components are a solid‑phase coated with purified BHV‑1 gE antigen (either as recombinant protein or as part of a whole‑virus lysate) and a detection conjugate consisting of horseradish peroxidase (HRPO)-labeled monoclonal antibody specific to a dominant gE epitope. In this format, antibodies from infected cattle compete with the labeled conjugate, reducing the color signal, while vaccinated or naïve animals show full conjugate binding.
A BHV‑1 DIVA diagnostic test depends on a competitive ELISA that detects antibodies against the vaccine‑deleted glycoprotein E. The two critical raw materials are a gE‑coated microwell and an HRPO‑conjugated anti‑gE monoclonal antibody; only field‑infected animals generate anti‑gE antibodies that block the conjugate and dim the signal.
Understanding the DIVA Principle for BHV‑1
The Role of Marker Vaccines
Marker vaccines against Bovine Herpesvirus 1 are live or inactivated viruses from which the glycoprotein E (gE) gene has been removed.
Because gE is non‑essential for replication but highly immunogenic during natural infection, it creates a serological gap between vaccinated and field‑exposed cattle.
Animals receiving the gE‑deleted vaccine never encounter the gE protein, so they remain seronegative for anti‑gE antibodies, while wild‑type infection triggers a robust anti‑gE response.
How the Competitive ELISA Detects Infection vs. Vaccination
The assay exploits this gap by directly targeting the missing protein.
When a serum or plasma sample is added, any anti‑gE antibodies present will compete for binding with the HRPO‑conjugated monoclonal antibody.
Infected animals: high anti‑gE levels block the conjugate → low color signal.
Vaccinated or naïve animals: no anti‑gE blockers → unimpeded conjugate binding → high color signal.
This binary readout makes interpretation straightforward and allows clear discrimination without ambiguity.
Core Reagent Components of the Assay
Solid‑Phase Antigen: Recombinant gE
The microwell plate is coated with BHV‑1 gE, either as a purified recombinant protein or as part of an inactivated whole‑virus preparation.
Recombinant gE is preferred because it can be produced at high purity and consistency, eliminating the risk of contaminating viral proteins that could cause cross‑reactivity.
The coating must preserve the native‑like conformation of the epitope recognized by the monoclonal conjugate, so buffer conditions and blocking steps are critical.
Enzyme‑Labeled Monoclonal Antibody Conjugate
The detection reagent is an HRPO‑conjugated monoclonal antibody that binds specifically to an immunodominant gE epitope.
This conjugate must have high affinity and be titrated carefully to give a steep competition curve—small amounts of competing sample antibody should produce a measurable signal drop.
Because the conjugate recognizes the same surface the solid‑phase antigen presents, the assay format is classified as a competitive or blocking ELISA.
Critical Quality Attributes for Reagents
- Purity: Recombinant gE must be free of E. coli or cell‑culture contaminants that cause non‑specific blocking.
- Epitope integrity: The monoclonal antibody must target an epitope conserved across all BHV‑1 field strains, otherwise false negatives occur.
- Lot‑to‑lot consistency: Both antigen and conjugate require rigorous QC to maintain a consistent cut‑off value, which is essential for regulatory approval.
Designing a Reliable Competitive ELISA Workflow
Assay Steps and Signal Interpretation
A typical protocol includes:
- Coating the plate with gE antigen overnight.
- Incubating diluted test serum alongside the HRPO‑conjugate (simultaneous competition format).
- Washing to remove unbound antibodies and conjugate.
- Adding TMB substrate and stopping after a fixed time.
Samples with optical density below a predetermined threshold are reported as infected (gE antibody positive), while those above the threshold are considered gE‑negative.
Avoiding Cross‑reactivity and Non‑specific Binding
High non‑specific binding (NSB) can blur the distinction between infected and vaccinated populations.
Using a blocking buffer optimized for bovine serum and a pure recombinant gE coating minimizes NSB.
Including a negative control well (no antigen or a heterologous protein) helps detect samples with interfering substances like heterophile antibodies.
Trade‑offs and Common Pitfalls
Balancing Sensitivity and Specificity
A competitive ELISA built on a single epitope can be extremely specific, but may miss infections if the epitope mutates in the field.
Pairing a recombinant gE coating with a monoclonal that recognizes a conserved linear epitope provides a good balance, but developers should periodically verify reactivity against circulating isolates.
Dependence on High‑Purity Recombinant Antigens
If the recombinant gE preparation contains aggregates or misfolded material, the effective coating concentration may vary, shifting the competition curve and affecting cut‑off reliability.
Production in eukaryotic expression systems (e.g., insect or mammalian cells) often yields better conformational integrity, but at a higher cost than bacterial expression.
Potential for Vaccine‑Induced Non‑Specific Interference
Although gE‑deleted vaccines do not express the full gE protein, some vaccinated animals may still produce low‑level cross‑reactive antibodies that weakly bind other viral antigens present in a whole‑virus coating.
To mitigate this, developers typically use recombinant gE alone as the coating rather than whole‑virus lysate, removing the risk of vaccine‑induced background.
Making the Right Choice for Your Development Goals
The optimal reagent selection and assay design depend on the specific performance profile you need.
- If your primary focus is maximum regulatory acceptance: Use a highly purified recombinant gE antigen expressed in a eukaryotic system and an extensively validated anti‑gE monoclonal conjugate with documented strain‑coverage data.
- If your primary focus is rapid, low‑cost field screening: A whole‑BHV‑1 coating may reduce upfront cost, but strict validation against gE‑deleted vaccine‑derived samples is essential to confirm no false‑positives emerge.
- If your primary focus is integrating BHV‑1 into a multiplex respiratory panel: Engineer the gE epitope onto a bead‑based platform and ensure the monoclonal conjugate does not cross‑react with reagents targeting other bovine pathogens.
A carefully sourced gE antigen and a high‑affinity monoclonal conjugate are the non‑negotiable pillars of any successful BHV‑1 DIVA test—master these, and you build a diagnostic that delivers unambiguous, field‑ready results.
Summary Table:
| Component / Factor | Specification / Selection | Key Role in Assay |
|---|---|---|
| Immunoassay Format | Competitive (Blocking) ELISA | Enables clear differentiation between wild-type infection and gE-deleted vaccination |
| Solid-Phase Antigen | Recombinant BHV-1 gE Protein | Provides native epitope conformation while eliminating cross-reactive viral contaminants |
| Detection Conjugate | HRPO-conjugated Anti-gE Monoclonal Antibody | Competes with serum antibodies; lower signal indicates positive anti-gE field infection |
| Optimization Focus | Epitope Conservation & NSB Control | Prevents false positives/negatives and ensures robust cut-off consistency across lots |
Accelerate Your Diagnostic Assay Development with CamelBio
Developing a high-performance BHV-1 DIVA competitive ELISA requires top-tier recombinant antigens and high-affinity monoclonal conjugates. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you are scaling production or optimizing epitope specificity, our team is ready to support your diagnostic pipeline. Contact us today to discuss your raw material and assay development needs!